Factors influencing the decision to discontinue treatment due to chemotherapy-induced peripheral neuropathy among patients with metastatic breast cancer: a best–worst scaling
Radwan R, Bridges J, Hertz D, Lustberg M, Vachhani H, Hickey Zacholski E, Sheppard V, Salgado T. Factors influencing the decision to discontinue treatment due to chemotherapy-induced peripheral neuropathy among patients with metastatic breast cancer: a best–worst scaling. Supportive Care In Cancer 2025, 33: 467. PMID: 40347310, PMCID: PMC12065726, DOI: 10.1007/s00520-025-09508-4.Peer-Reviewed Original ResearchConceptsChemotherapy-induced peripheral neuropathyMetastatic breast cancerRisk of treatment discontinuationLong-term neuropathyCancer treatment optionsTreatment discontinuationTreatment optionsPeripheral neuropathyBreast cancerReduced riskNeuropathy symptomsBest-worst scalingNeurotoxic chemotherapyTherapeutic outcomesLoved onesNeuropathyPatientsCancerResultsThe sampleMethodsAn online surveyWomenScoresConclusionWhenRiskChemotherapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply